Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001.
Melissa A BurnsAndrew E PlaceKristen E StevensonAlejandro GutiérrezSuzanne ForrestYana PikmanLynda M VroomanMarian H HarrisSarah K HuntJane E O'BrienBarbara L AsselinUma H AthaleLuis A ClavellPeter D ColeLisa M GennariniJustine M KahnKara M KellyCaroline LaverdiereJean-Marie LeclercBruno MichonMarshall A SchorinMaria-Luisa SulisJennifer J G WelchDonna S NeubergStephen E SallanLewis B SilvermanPublished in: Pediatric blood & cancer (2020)
Together, our findings demonstrate that ETP phenotype, end-induction MRD, and PI3K pathway mutation status are prognostically relevant in pediatric T-ALL and should be considered for risk classification in future trials. DFCI Protocols 05-001 and 11-001 are registered at www.clinicaltrials.gov as NCT00165087 and NCT01574274, respectively.